Focuses on ex vivo genome editing and nonviral delivery for liver therapeutics. Develops electroporation workflows that maintain viability and improve engraftment, integrates hepatocyte transplantation, and validates clinical‑grade processes in preclinical metabolic liver disease models and disease models.